Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial

359Citations
Citations of this article
99Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We used data from the Fracture Intervention Trial to assess the relationship change in bone turnover after 1 year of alendronate or placebo treatment and subsequent hip, non-spine, and spine fracture risk among 6186 postmenopausal women. In the alendronate group (n = 3105), greater reductions in one or more biochemical marker were associated with a lower risk of fracture. Introduction: There are few data on the relationship between short-term change in biochemical markers of bone turnover and non-spine fracture risk among bisphosphonate-treated women, and the clinical use of such measurements is unknown. Materials and Methods: We measured biochemical markers of bone turnover (bone-specific alkaline phosphatase [bone ALP], intact N-terminal propeptide of type I collagen, and C-terminal crosslinked telopeptide of type 1 collagen) and BMD of the spine and hip at baseline and after 1 year of alendronate or placebo. During a mean follow-up of 3.6 years, 72 hip, 786 non-spine, and 336 vertebral fractures were documented. Results and Conclusions: Each 1 SD reduction in 1-year change in bone ALP was associated with fewer spine (odds ratio = 0.74; CI: 0.63, 0.87), non-spine (relative hazard [RH] = 0.89; CI: 0.78, 1.00; p < 0.050), and hip fractures (RH = 0.61; CI: 0.46, 0.78). Alendronate-treated women with at least a 30% reduction in bone ALP had a lower risk of non-spine (RH = 0.72; CI: 0.55, 0.92) and hip fractures (RH = 0.26; CI: 0.08, 0.83) relative to those with reductions <30%. We conclude that greater reductions in bone turnover with alendronate therapy are associated with fewer hip, non-spine, and vertebral fractures, and the effect is at least as strong as that observed with 1-year change in BMD. © 2004 American Society for Bone and Mineral Research.

References Powered by Scopus

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

3578Citations
N/AReaders
Get full text

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

3188Citations
N/AReaders
Get full text

Vertebral fracture assessment using a semiquantitative technique

3104Citations
N/AReaders
Get full text

Cited by Powered by Scopus

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

1143Citations
N/AReaders
Get full text

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards

948Citations
N/AReaders
Get full text

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

530Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., … Delmas, P. D. (2004). Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. Journal of Bone and Mineral Research, 19(8), 1250–1258. https://doi.org/10.1359/JBMR.040512

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 36

64%

Researcher 9

16%

Professor / Associate Prof. 7

13%

Lecturer / Post doc 4

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 44

73%

Agricultural and Biological Sciences 6

10%

Biochemistry, Genetics and Molecular Bi... 6

10%

Engineering 4

7%

Save time finding and organizing research with Mendeley

Sign up for free